Population Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal Impairment PAGE 29 (2021) Abstr 9668. Mezzalana E, Tomita Y, Hansson E, Mazuir F, Wellhagen G, Ooi QX, Kitamura A, Nemoto D, Bolze S. ConferenceMetabolicMIDDPharmacometricsSpecial/specific populations Pharmetheus Affiliates Senior Consultant Enrica Mezzalana See bio Senior Consultant, Regulatory Affairs Emma Hansson See bio Senior Consultant Qing Xi Ooi See bio